Efficacy and safety of thalidomide, lenalidomide, and bortezomib for poems syndrome

Key Points

• The combination therapies show promising efficacy in treating POEMS syndrome, a rare blood disorder.
• Thalidomide, lenalidomide, and bortezomib enhance treatment outcomes and safety profiles for patients.
• Observational analysis across multiple cohorts confirms improved patient conditions with these medications.
• Clinical implications highlight the need for broader access and further validation of these treatment options.